Free Design Audit Available - Click Here for Details

FDA approves expanded MRI labeling for Abbott Proclaim neurostim

Abbott (NYSE: ABT)+ announced today that the FDA approved expanded MRI labeling for its Proclaim DRG neurostimulation system.

Proclaim DRG provides targeted relief for people with complex regional pain syndrome (CRPS) types I and II of the lower limbs. It stimulates the dorsal root ganglion (DRG) clusters of nerve cells found along the spine.

Abbott says four out of five people who receive Proclaim DRG stimulation experience significant pain relief and improved quality of life.

The expanded labeling allows patients to receive full-body MRI scans while implanted with the device.

MRI can help assess the progression of CRPS. Having Proclaim DRG allow for MRI scans anywhere in the body (within approved parameters) provides value to patients and radiologists.

Sign up for Blog Updates